nach oben

Erschienen in:

01.07.2008 | Original Article

Changes of cytokines in cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy

verfasst von: Hidenari Nagai, Daisuke Miyaki, Teppei Matsui, Masahiro Kanayama, Katsuya Higami, Kouichi Momiyama, Takashi Ikehara, Manabu Watanabe, Yasukiyo Sumino, Kazumasa Miki

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Tumor necrosis factor (TNF) induces cancer cell-specific apoptosis by binding to a TNF-related apoptosis-inducing ligand. Binding of the Fas ligand on cytotoxic T lymphocytes to the Fas receptor on hepatocytes is also known to induce apoptosis. The aim of this study was to clarify changes of cytokines in patients with liver cirrhosis (LC) and advanced hepatocellular carcinoma (aHCC) receiving intra-arterial combination chemotherapy.

Methods

Twenty-one adult Japanese LC patients with aHCC received intra-arterial combination chemotherapy. The serum levels of TNF-alpha, soluble TNF receptor-I (sTNFr-I), soluble Fas ligand (sFas L), and soluble Fas (sFas) were evaluated.

Results

Thirteen of the 21 patients (group R) showed an objective response, while the other eight patients (group N) showed no response. The serum level of TNF-alpha was lower after chemotherapy than before chemotherapy in group N, but there was no difference of serum sTNFr-I levels between before and after chemotherapy and there were also no differences between the two groups. The serum sFas levels were higher after chemotherapy than before chemotherapy in group N, while there was no difference among groups.

Conclusions

These results indicate that a high serum TNF-alpha level and a low serum sFas level might be important for successful combined arterial chemotherapy in LC patients with aHCC.

Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Onishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928PubMedCrossRef

Nagasue N, Yukaya H, Hamada T, Hirosue S, Kanashima R, Inokuchi K (1984) The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 54:1461–1465PubMedCrossRef

Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, Kirishima S, Suga T, Takahashi M (1995) The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 52:295–299PubMedCrossRef

Murata K, Shiraki K, Kawakita T, Yamamoto N, Okano H, Nakamura M, Sakai Takahisa, Deguchi M, Ohmori S, Nakano T (2003) Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 23:1719–1722PubMed

Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, Eriguchi N, Aoyagi S, Takikawa K (1999) Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 6:587–591PubMed

Nagai H, Matsui T, Kanayama M, Momiyama K, Ikoma A, Okano N, Ikehara T, Matsumaru K, Watanabe M, Iida K, Ishii K, Sumino Y, Miki K (2007) Assessment of combined intra-arterial low-dose 5-fluorouracil, cisplatin, and leucovolin chemotherapy for patients with advanced hepatocellular carcinoma using the Japan integrated staging score. J Med Soc Toho 54:21–28

Nagai H, Kanayama M, Higami K, Momiyama K, Ikoma A, Okano N, Matsumaru K, Watanabe M, Ishii K, Sumino Y, Miki K (2007) Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. World J Gastroenterol 13(2):280–284PubMed

Scanlon KJ, Newman EW, Lu Y, Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83:8923–8925PubMedCrossRef

Shirasaka T, Shimamoto Y, Ohsimo H, Saito M, Fukusima M (1993) Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 32:167–172PubMedCrossRef

10.

Ensminger WD, Gyves JW (1983) Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10:176–182PubMed

11.

Shiraki K, Yamanaka T, Inoue H, Kawakita T, Enokimura N, Okano Hiroshi, Sugimoto K, Murata K, Nakano T (2005) Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. Int J Oncol 26:1273–1281PubMed

12.

Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ (2000) Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60:847–853PubMed

13.

Wenn J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K (2000) Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 96:3900–3906

14.

Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11:S86–S96PubMedCrossRef

15.

Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, Kondo M, Damdinsuren B, Ota H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Yagita H, Monden M (2004) Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of onterferon-alpha/5-fluorouracil against hepatocellular carcinoma. Clin Cancer Res 10:7884–7895PubMedCrossRef

16.

Nagata S, Golstein P (1995) The Fas death factor. Science 267:1449–1455PubMedCrossRef

17.

Armitage RJ (1994) Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 6:407–413PubMedCrossRef

18.

Nakamura M, Nagano H, Sakon M, Yamamoto T, Ota H, Wada H, Damdisuren B, Noda T, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Dono K, Monden M (2007) Role of the Fas/FasL pathway in combination therapy with interferon-a and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol 46:77–88PubMedCrossRef

19.

Iwamiya T, Sawada S, Ohta Y (1994) Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 33(Suppl):S134–S138PubMedCrossRef

20.

Kudo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for new staging system, the Japan integrated staging score (JIS score). J Gastroenterol 38:207–215PubMedCrossRef

21.

Beutler B, Cerami A (1998) Cachectin (tumor necrosis factor): a macrophage hormone governing cellular metabolism and inflammatory response. Endocr Rev 9:57–66CrossRef

22.

Tracey KJ, Vlassara H, Cerami A (1989) Cachectin/tumor necrosis factor. Lancet 1(8647):1122–1126PubMedCrossRef

23.

Brockhause M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H (1990) Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 87:3127–3131CrossRef

24.

Hohmann HP, Remy R, Brockhause M, Van Loon AP (1989) Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J Biol Chem 264:1429–1434

25.

Ruberti G, Cascino I, Papoff G, Eramo A (1996) Fas splicing variants and their effect on apoptosis. Adv Exp Med Biol 406:125–134PubMed

26.

Iio S, Hayashi N, Mita E, Ueda K, Mochizuki K, Hiramatsu N, Kanto T, Sasaki Y, Kasahara A, Hori M (1998) Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 29:517–523PubMedCrossRef

27.

Zylberberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P, Bach JF, Brechot C, Zavala F (1999) Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 30:185–191PubMedCrossRef

28.

Waage A, Liabakk N, Lien E, Lamvik J, Espevik T (1992) p55 and p75 tumor necrosis factor receptors in patients with chronic lymphocytic leukemia. Blood 80:2577–2583PubMed

29.

Marinos G, Naoumov NV, Rossol S, Torre F, Wong PY, Gallati H, Portmann B, Williams R (1995) Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 108:1453–1463PubMedCrossRef

30.

Seishima M, Takemura M, Saito K, Ando K, Noma A (1997) Increased serum soluble Fas (sFas) concentrations in HCV-positive patients with liver cirrhosis. J Hepatol 27:424–425PubMedCrossRef

31.

Jodo S, Kobayashi S, Nakajima Y, Matsunaga T, Nakayama N, Ogura N, Kayagaki N, Okumura K, Koike T (1998) Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol 112:166–1671PubMedCrossRef

32.

Hayashi N, Mita E (1997) Fas system and apoptosis in viral hepatitis. J Gastroenterol Hepatol 12:S223–S226PubMedCrossRef

33.

Peng Z, Tang H, Ling Y, Han G (2001) Apoptosis and Fas system are significantly involved in the process of liver cirrhosis converting into HCC. J Tongji Med Univ 21(2):126–129PubMedCrossRef

Titel: Changes of cytokines in cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy
verfasst von: Hidenari Nagai
Daisuke Miyaki
Teppei Matsui
Masahiro Kanayama
Katsuya Higami
Kouichi Momiyama
Takashi Ikehara
Manabu Watanabe
Yasukiyo Sumino
Kazumasa Miki
Publikationsdatum: 01.07.2008
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2008
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-007-0602-9

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Changes of cytokines in cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy